TY - JOUR
T1 - Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents
AU - Bodo, Sahra
AU - Colas, Chrystelle
AU - Buhard, Olivier
AU - Collura, Ada
AU - Tinat, Julie
AU - Lavoine, Noémie
AU - Guilloux, Agathe
AU - Chalastanis, Alexandra
AU - Lafitte, Philippe
AU - Coulet, Florence
AU - Buisine, Marie-Pierre
AU - Ilencikova, Denisa
AU - Ruiz-Ponte, Clara
AU - Kinzel, Miriam
AU - Grandjouan, Sophie
AU - Brems, Hilde
AU - Lejeune, Sophie
AU - Blanché, Hélène
AU - Wang, Qing
AU - Caron, Olivier
AU - Cabaret, Odile
AU - Svrcek, Magali
AU - Vidaud, Dominique
AU - Parfait, Béatrice
AU - Verloes, Alain
AU - Knappe, Ulrich J
AU - Soubrier, Florent
AU - Mortemousque, Isabelle
AU - Leis, Alexander
AU - Auclair-Perrossier, Jessie
AU - Frébourg, Thierry
AU - Fléjou, Jean-François
AU - Entz-Werle, Natacha
AU - Leclerc, Julie
AU - Malka, David
AU - Cohen-Haguenauer, Odile
AU - Goldberg, Yael
AU - Gerdes, Anne-Marie
AU - Fedhila, Faten
AU - Mathieu-Dramard, Michèle
AU - Hamelin, Richard
AU - Wafaa, Badre
AU - Gauthier-Villars, Marion
AU - Bourdeaut, Franck
AU - Sheridan, Eamonn
AU - Vasen, Hans
AU - Brugières, Laurence
AU - Wimmer, Katharina
AU - Muleris, Martine
AU - Duval, Alex
AU - European Consortium “Care for CMMRD”
N1 - Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.
PY - 2015/10/1
Y1 - 2015/10/1
N2 - BACKGROUND & AIMS: Patients with bi-allelic germline mutations in mismatch repair (MMR) genes (MLH1, MSH2, MSH6, or PMS2) develop a rare but severe variant of Lynch syndrome called constitutional MMR deficiency (CMMRD). This syndrome is characterized by early-onset colorectal cancers, lymphomas or leukemias, and brain tumors. There is no satisfactory method for diagnosis of CMMRD because screens for mutations in MMR genes are noninformative for 30% of patients. MMR-deficient cancer cells are resistant to genotoxic agents and have microsatellite instability (MSI), due to accumulation of errors in repetitive DNA sequences. We investigated whether these features could be used to identify patients with CMMRD.METHODS: We examined MSI by PCR analysis and tolerance to methylating or thiopurine agents (functional characteristics of MMR-deficient tumor cells) in lymphoblastoid cells (LCs) from 3 patients with CMMRD and 5 individuals with MMR-proficient LCs (controls). Using these assays, we defined experimental parameters that allowed discrimination of a series of 14 patients with CMMRD from 52 controls (training set). We then used the same parameters to assess 23 patients with clinical but not genetic features of CMMRD.RESULTS: In the training set, we identified parameters, based on MSI and LC tolerance to methylation, that detected patients with CMMRD vs controls with 100% sensitivity and 100% specificity. Among 23 patients suspected of having CMMRD, 6 had MSI and LC tolerance to methylation (CMMRD highly probable), 15 had neither MSI nor LC tolerance to methylation (unlikely to have CMMRD), and 2 were considered doubtful for CMMRD based on having only 1 of the 2 features.CONCLUSION: The presence of MSI and tolerance to methylation in LCs identified patients with CMMRD with 100% sensitivity and specificity. These features could be used in diagnosis of patients.
AB - BACKGROUND & AIMS: Patients with bi-allelic germline mutations in mismatch repair (MMR) genes (MLH1, MSH2, MSH6, or PMS2) develop a rare but severe variant of Lynch syndrome called constitutional MMR deficiency (CMMRD). This syndrome is characterized by early-onset colorectal cancers, lymphomas or leukemias, and brain tumors. There is no satisfactory method for diagnosis of CMMRD because screens for mutations in MMR genes are noninformative for 30% of patients. MMR-deficient cancer cells are resistant to genotoxic agents and have microsatellite instability (MSI), due to accumulation of errors in repetitive DNA sequences. We investigated whether these features could be used to identify patients with CMMRD.METHODS: We examined MSI by PCR analysis and tolerance to methylating or thiopurine agents (functional characteristics of MMR-deficient tumor cells) in lymphoblastoid cells (LCs) from 3 patients with CMMRD and 5 individuals with MMR-proficient LCs (controls). Using these assays, we defined experimental parameters that allowed discrimination of a series of 14 patients with CMMRD from 52 controls (training set). We then used the same parameters to assess 23 patients with clinical but not genetic features of CMMRD.RESULTS: In the training set, we identified parameters, based on MSI and LC tolerance to methylation, that detected patients with CMMRD vs controls with 100% sensitivity and 100% specificity. Among 23 patients suspected of having CMMRD, 6 had MSI and LC tolerance to methylation (CMMRD highly probable), 15 had neither MSI nor LC tolerance to methylation (unlikely to have CMMRD), and 2 were considered doubtful for CMMRD based on having only 1 of the 2 features.CONCLUSION: The presence of MSI and tolerance to methylation in LCs identified patients with CMMRD with 100% sensitivity and specificity. These features could be used in diagnosis of patients.
KW - Adaptor Proteins, Signal Transducing
KW - Adenosine Triphosphatases
KW - Adult
KW - Antineoplastic Agents, Alkylating
KW - Biomarkers, Tumor
KW - Brain Neoplasms
KW - Caco-2 Cells
KW - Case-Control Studies
KW - Colorectal Neoplasms
KW - Colorectal Neoplasms, Hereditary Nonpolyposis
KW - DNA Mutational Analysis
KW - DNA Repair Enzymes
KW - DNA-Binding Proteins
KW - Drug Resistance, Neoplasm
KW - Female
KW - Genetic Predisposition to Disease
KW - Genetic Testing
KW - Germ-Line Mutation
KW - HCT116 Cells
KW - Heredity
KW - Humans
KW - Lymphocytes
KW - Male
KW - Methylation
KW - Microsatellite Instability
KW - Multiplex Polymerase Chain Reaction
KW - MutS Homolog 2 Protein
KW - Neoplastic Syndromes, Hereditary
KW - Nuclear Proteins
KW - Phenotype
KW - Predictive Value of Tests
KW - Reproducibility of Results
KW - Transfection
KW - Young Adult
U2 - 10.1053/j.gastro.2015.06.013
DO - 10.1053/j.gastro.2015.06.013
M3 - Journal article
C2 - 26116798
SN - 0016-5085
VL - 149
SP - 1017-29.e3
JO - Gastroenterology
JF - Gastroenterology
IS - 4
ER -